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Cardiovascular function depends on patent blood
vessel formation by endothelial cells (ECs). However,
the mechanisms underlying vascular ‘‘tubulogene-
sis’’ are only beginning to be unraveled. We show
that endothelial tubulogenesis requires the Ras inter-
acting protein 1, Rasip1, and its binding partner, the
RhoGAP Arhgap29. Mice lacking Rasip1 fail to form
patent lumens in all blood vessels, including the early
endocardial tube. Rasipl null angioblasts fail to prop-
erly localize the polarity determinant Par3 and
display defective cell polarity, resulting in mislocal-
ized junctional complexes and loss of adhesion
to extracellular matrix (ECM). Similarly, depletion
of either Rasip1 or Arhgap29 in cultured ECs
blocks in vitro lumen formation, fundamentally alters
the cytoskeleton, and reduces integrin-dependent
adhesion to ECM. These defects result from in-
creased RhoA/ROCK/myosin II activity and blockade
of Cdc42 and Rac1 signaling. This study identifies
Rasip1 as a unique, endothelial-specific regulator
of Rho GTPase signaling, which is essential for blood
vessel morphogenesis.
INTRODUCTION
Tubulogenesis is a fundamental process that is essential for the
development of many tubular organs, including the cardiovas-
cular system. The first embryonic blood vessels form on embry-
onic day 8.0 (E8.0) via a process termed vasculogenesis. Vascu-
logenesis is comprised of three principal steps: angioblast (EC
progenitor) specification, followed by ‘‘cord’’ formation, and ulti-
mately, blood vessel lumen formation, or ‘‘tubulogenesis.’’ In the
mouse, angioblasts arise within the mesoderm and migrate to
adhere with each other in primitive lumenless cords, presaging
the paired dorsal aortae, endocardium, and yolk sac vascular
plexus. As cords undergo tubulogenesis, ECs create a central
lumen, allowing blood flow. The transformation of solid endothe-
lial cords or individual ECs into patent vascular tubes is thus526 Developmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Ifundamental to establishing a seamless, functional circulatory
system and has been the focus of growing interest (Davis
et al., 2007; Iruela-Arispe and Davis, 2009; Kamei et al., 2006;
Kucera et al., 2007; Strilic et al., 2009).
The precise cellular and molecular mechanistic basis for this
morphogenetic process in vivo is still not completely under-
stood. While epithelial and endothelial in vitro systems have
long providedmodels to dissectmechanisms of lumen formation
(Andrew and Ewald, 2010; Bayless and Davis, 2002; Davis et al.,
2007; Iruela-Arispe and Davis, 2009; Koh et al., 2008; Koh et al.,
2009; O’Brien et al., 2002), in vivo studies have only begun to
elucidate underlying regulatory molecules responsible for
vascular tubulogenesis (Kamei et al., 2006; Strilic et al., 2009;
Zovein et al., 2010). To date, molecular mechanisms linked to
vascular lumen formation have involved either widely expressed
regulatory factors, such as Rho family GTPases or integrins
(Bayless and Davis, 2002; Connolly et al., 2002; Zovein et al.,
2010), or endothelial factors whose ablation hinders lumen
formation in only subsets of vessels (Carmeliet et al., 1999; Strilic
et al., 2009), leaving open the question of whether any endothe-
lial-restricted factor might broadly regulate vessel tubulogene-
sis. Identifying critical endothelial-specific modulators of these
pathways has thus represented an important challenge. Under-
standing, and potentially clinically targeting, the formation and
maintenance of vascular lumens is directly relevant to both anti-
angiogenic and vascular-targeted therapies (Bergers and Hana-
han, 2008; Reardon et al., 2008; Siemann et al., 2005).
Here, we report that blood vessel tube formation requires the
endothelial-restricted Ras interacting protein 1, Rasip1. Mice
lacking Rasip1 fail to form patent lumens in all blood vessels,
large and small, and endocardial development is arrested
at the onset of cardiovascular development. We show that
Rasip1 acts as a tissue-specific regulator of GTPase signaling,
promoting proper establishment of cell polarity, as well as regu-
lating cytoskeletal and cell adhesion changes to drive endothelial
tube morphogenesis. Rasip1 regulates activity of Rho GTPases
in part by recruiting the RhoA-specific GTPase activating protein
(GAP) Arhgap29. Depletion of either Rasip1, or Arhgap29, in
cultured ECs aberrantly elevates RhoA/ROCK/Myosin II
signaling and blocks Cdc42/Rac1 signaling. As a result, b1 integ-
rin adhesion to ECM is suppressed, the polarity determinant
Par3 fails to localize properly, and ectopic tight junctions form
at the apical membrane. Our studies identify Rasip1 as a criticalnc.
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tecture, and adhesion, which is essential for EC morphogenesis
and blood vessel tubulogenesis.
RESULTS
Rasip1 Is Essential for Cardiovascular Development
To identify genes that regulate blood vessel morphogenesis, we
transcriptionally profiled isolated embryonic aortic ECs (Affyme-
trix, data not shown). Rasip1 (Mitin et al., 2004) was identified as
a highly enriched sequence in E8.5 aortic ECs, which was
expressed exclusively in ECs of murine, amphibian and fish
embryos throughout embryogenesis (Figures 1A–1D) (Xu et al.,
2009a). To examine whether Rasip1 might regulate vasculogen-
esis in higher vertebrates, we generated mice lacking Rasip1
function (Figure S1). Heterozygous Rasip1mice were phenotyp-
ically normal and viable, while the null mutation was embryonic
lethal. Homozygous null embryos appeared grossly normal at
E8.25, but were dead by E10.5 (Figures S2A and S2B and data
not shown). At E9.5, Rasip1/ mutant embryos displayed
growth retardation and widespread edema (Figures 1E and
1F), and their yolk sac appeared smooth, lacking the hierarchical
vascular network evident in heterozygous controls (Figures 1G
and 1H). No significant differences were found in placental
tissues (data not shown).
Blood Vessel Tubulogenesis Requires Rasip1
To understand the origins of the observed cardiovascular failure
in Rasip1/ mutants, we sought to characterize developing
blood vessels. A Flk1-LacZ allele was bred into the Rasip1 null
line (Shalaby et al., 1995). Initial angioblast numbers and distribu-
tionwere normal (Figures S2C and S2D), indicating that Rasip1 is
not required for angioblast specification, proliferation, or
patterning. However, by E9.5, mutant vessels failed to remodel
from an initial plexus into their typical hierarchical array of large
and small vessels, both in the yolk sac (Figures 1I and 1J) and
embryonic tissues (Figures 1K and 1L). In addition, arteriovenous
differentiation failed in Rasip1/ vessels, as assessed by the
arterial marker Connexin40 (Gja5) and EphB4-LacZ (Wang
et al., 1998) (Figures 1M–1P). Together, these results showed
that development of embryonic blood vessels was severely
impaired in the absence of Rasip1.
Remodeling and arteriovenous differentiation defects are hall-
mark effects of hemodynamic failure, as both processes depend
on blood flow (le Noble et al., 2004). Therefore, to identify
possible vessel occlusions in Rasip1 mutants that would
hinder blood circulation, we examined the first major embryonic
vessels, the paired dorsal aortae. In both Rasip1+/ and
Rasip1/ embryos, E8.0–8.5 preaortal angioblasts aligned
normally in two parallel rows; however, they appeared distinctly
narrower in mutant embryos (Figures S2E–S2L), often displaying
visible occlusions (Figures 1Q and 1R). Indeed, sections
revealed that patent, continuous lumens were globally absent
in all blood vessels, including those of the dorsal aortae (Figures
1S–1V), endocardium (Figures 1W–1X), yolk sac (Figure 1Y–1Z0),
vitelline artery, inflow tracts, and allantois (data not shown).
Absence of vascular tubes was evident at all stages examined,
from the onset of cord formation at the 1somite (1S) stage
and throughout the entire time frame of normal tubulogenesisDeve(2S to 6S) (Figures S2E–S2L and data not shown). We examined
developmental intermediates at each somite stage (from 1S to
12S, at E8.0–8.5), as well as at E9.0, E9.5, and E10.5. Defects
did not result from failed proliferation, as similar numbers of
ECs were present in Rasip1+/ versus Rasip1/ aortae, and
we found no proliferation defects (Figures S2M–S2O). Given
that failure of tubulogenesis occurred at the onset of vessel
formation, prior to the onset of blood flow, and that EC prolifer-
ation was not affected, we reasoned that loss of Rasip1 resulted
in morphogenetic failure because of cellular defects intrinsic to
mutant angioblasts.
Rasip1 Binding Partners
While Rasip1 had previously been shown to bind Ras GTPases
by in vitro pull down assays (Mitin et al., 2004), its physiological
binding partners in endothelium and its downstream signaling
pathways have remained unknown. To elucidate the molecular
mechanism of Rasip1 function during vasculogenesis and lumen
formation, we sought to determine its binding partners by two-
step affinity purification andmass spectrometry, using a tetracy-
cline-inducible stable endothelial cell line (MS1Rasip1-FLAG)
(Figures S3A–S3C). Among several putative Rasip1 binding part-
ners identified (Figure 2A) were two proteins of particular interest
because of their previous implication in vascular development:
non-muscle myosin heavy-chain IIA (NMHCIIA) and a RhoA-
specific GAP, Arhgap29 (Figures S3D and S3E).
NMHCIIA is an important motor protein in the actomyosin
complex. NMHCIIA and MLC (myosin light chain) together
comprise myosin II, which modulates diverse processes such
as cell structure, adhesion, contractility, and motility (Conti and
Adelstein, 2008; Even-Ram and Yamada, 2007). NMHCIIA often
exerts its regulatory control by acting as a scaffold for signaling
molecules, such as kinases and Rho GTPase guanine nucleotide
exchange factors (GEFs) (Even-Ram et al., 2007). Recently, it
was reported that in VEGF haploinsufficient embryos, NMHCIIA
failed to be recruited to the luminal membrane of dorsal aortic
ECs, which failed to form vascular lumens (Strilic et al., 2009).
NMHCIIA was proposed to regulate actomyosin tension of the
cell membrane, driving lumen expansion. In Rasip1/ failed
vessels (Figures S4A–S4H) and Rasip1 siRNA depleted cells
(Figures S4I–S4L), levels of NMHCIIA at the EC-EC interface
appear unchanged, suggesting that recruitment of NMHCIIA to
the cell membrane was Rasip1-independent. We therefore
reasoned that NMHCIIA activity and function, rather than levels,
might be altered in Rasip1/ mutants.
Arhgap29 (PARG1), the other identified Rasip1 binding
partner, was known to be expressed in fish vasculature (Gomez
et al., 2009) and to possess a GAP domain for RhoA (Myagmar
et al., 2005). In mouse embryos, we found that Arhgap29 protein
was present in the ECs of the paired aortae during vasculogen-
esis, in a manner analogous to that reported in fish (Figure 2B).
In addition, Rasip1 and Arhgap29 were present together in
cytoplasmic punctae in cultured ECs (50% rate of overlap)
(Figure 2C).
Rasip1 and Arhgap29 Are Required for In Vitro
Lumen Formation
Overlap of Rasip1 and Arhgap29 in ECs, both in vivo and in vitro,
suggested that they were likely to function together during bloodlopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 527
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Figure 1. Rasip1 Is Essential for Vascular Tubulogenesis in All Blood Vessels
(A–D) Rasip1 expression is conserved in the embryonic vasculature across species shown by in situ hybridization: mouse (A, E9.5; B, E8.5 transverse section, left
dorsal aorta), Xenopus tropicalis (C, st.30), and zebrafish (D, 24 hpf).
(E–H) E9.5 littermate mouse embryos showing defects in Rasip1/ embryos (F) and yolk sacs (H).
(I–L)Whole-mount Flk1-lacZ beta-galactosidase staining ofRasip1+/ (I and K) andRasip1/ (J and L) yolk sacs (I and J) and embryonic heads (K and L), showing
narrow Rasip1/ blood vessels that fail to remodel.
(M–P) Connexin40 (Cx40 or Gja5) (M and N) or EphB4-lacZ (O and P) in littermate E9.5Rasip1+/ andRasip1/ yolk sacs (M and N) or embryos (O and P) showing
failed arterial (M and N) and venous (O and P) differentiation in Rasip1/ vessels.
(Q–Z0 ) Flk1-LacZ beta-galactosidase staining of littermate E8.5 (6 somite stage) Rasip1+/ and Rasip1/ embryos and tissues, in whole mount or section.
(Q and R) Ventral views of E8.5 embryonic paired dorsal aortae. Anterior is up. (S–V) Transverse sections of E8.5 embryos, through the trunk region, posterior
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Figure 2. Rasip1 and Arhgap29 Are Required for In Vitro EC Lumen Formation and Regulation of Small GTPase Signaling
(A) Silver staining of the affinity-purified Rasip1 complex. Marked bands were identified by mass spectrometry.
(B) Arhgap29 protein in E8.5 mouse embryonic aortic ECs, ventral view. Arrows, paired dorsal aortae. Scale bar, 50 mm.
(C) Rasip1 and Arhgap29 expression in cultured EC (MS1). Arrowheads, Rasip1/Arhgap29 colocalization in punctae. Nuclei, DAPI (blue).
(D) Western blots of Rasip1 and Arhgap29 following siRNA treatment of cultured HUVECs in 3D collagen matrices.
(E) Lumen formation is blocked in siRasip1-/siArhgap29-treated HUVECs cultured in 3D collagen matrices. Arrowheads, visible EC lumen.
(F) Quantification of lumen formation in control- or siRasip1-/siAhgap29- treated HUVECs.
(G and H) Cdc42, Rac1, and RhoA activities (G) and reduction of kinase signaling downstream of Cdc42/Rac1 pathway (H) in siRNA-treated HUVECs in 3D
cultures at 24 hr. Error bars represent standard deviation.
See also Figure S3.
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Rasip1 Directs Vascular Tubulogenesisvessel development. To assess the requirement for Rasip1 and
Arhgap29 during in vitro tubulogenesis, we used a HUVEC 3D
matrix assay that mimics the developmental process of vasculo-
genesis (Kamei et al., 2006; Sacharidou et al., 2010). To deter-
mine whether Rasip1 or Arhgap29 function was required for
EC lumen formation in vitro, siRNA-depleted cells (Figure 2D
and Figure S3F) were assessed for their lumen formation ability.
Strikingly, EC lumen formation was completely blocked in
siRNA-treated cells (Figures 2E and 2F). Movies of depleted cellsto the heart. (U and V) Close-up views, showing open lumens in Rasip1+/;Flk1-
(T andV). Sections throughhearts of E8.5 (WandX), showing absenceof a lumen in
(Y and Z) or section views (Y0 and Z0). Vascular tubes are absent in all Rasip1/
yolk sac; Scale bars, 500 mm (A, E, F, G, and H), 250 mm (C), 200 mm (K–P), 100 m
See also Figures S1 and S2.
Deveshowed that, although ECs extended cellular processes, these
would snap back and rarely maintain connections to the
surrounding matrix (Movies S2, S3, S5, and S6). In addition, cells
would dynamically make and break contacts with each other and
preliminary lumenal structures within individual ECs initiated but
quickly collapsed. In contrast, the control ECs would generate
and sustain lumens, maintain steady adherence to the surround-
ing matrix, and interconnect to form multicellular lumenal struc-
tures (Figures 2E and 2F and Movies S1 and S4).lacZ embryos (S and U) but lumenless cords in Rasip1/;Flk1-lacZ embryos
theendocardiumofRasip1/;Flk1-lacZembryos (X). Yolk sacs inwhole-mount
vessels examined. Arrows, dorsal aortae; Arrowheads, yolk sac vessels. Ys,
m (D, I, J, Q, R, Y, and Z), and 50 mm (B, S, T, U, V, W, X, Y, Z, Y0, and Z0).
lopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 529
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of Cdc42 and Rac1 during Lumen Formation
Previous in vitro studies have shown that vascular lumen forma-
tion depends on proper regulation of the Rho family of mono-
meric G proteins (Cdc42/Rac1/RhoA). Specifically, Cdc42 and
Rac1 activation were shown to be required for lumen formation
in 3D collagen matrix assays, while RhoA activation had the
opposite effect and suppressed it (Bayless and Davis, 2002,
2004; Iruela-Arispe and Davis, 2009; Nobes and Hall, 1995;
Sacharidou et al., 2010).
We thus examined Rasip1 and Arhgap29 regulation of Rho
GTPase activity using this same assay system and found mark-
edly decreased levels of activated Cdc42 and Rac1 levels in
siRNA-treated HUVECs (Figure 2G, Figure S3G, and data not
shown). In addition, we examined a kinase cascade downstream
of Cdc42 that was recently shown to be required for in vitro EC
lumen formation (Koh et al., 2008, 2009). As expected, signaling
downstream of Cdc42 and Rac1were impaired in the absence of
Rasip1 or Arhgap29, as the active (phosphorylated) form of key
GTPase effector kinases, such as pPak4, pSrc, pB-Raf, pC-Raf,
and pErk, were reduced in siRNA-depleted ECs (Figure 2H and
Figure S3H). Interestingly, although cell morphology and
behavior were similarly affected by absence of either Rasip1 or
Arhgap29, some differences in downstream signaling reduction
were reproducible (pSrc).
Rasip1 and Arhgap29 Regulate EC Architecture via
Repression of RhoA
In contrast to the reduced activities of Cdc42 and Rac1, we
found that RhoA activation was upregulated in the absence of
either Rasip1 or Arhgap29 (Figure 2G and Figure S3G). This
finding was consistent with the notion that RhoA antagonizes
lumen formation and must be kept at bay (Bayless and Davis,
2002). Because activated RhoAwas shown to suppress vascular
lumen maintenance via cytoskeletal modulation (Bayless and
Davis, 2004), we examined the EC cytoskeleton in the absence
of either Rasip1 or Arhgap29. Strikingly, individual knockdowns
of Rasip1 or Arhgap29 lead to nearly identical defects in EC
architecture (Figures 3A–3C). At higher resolution, we observed
a significant increase in actin stress fiber assembly (a process
dependent on RhoA) in the absence of either Rasip1 or Arhgap29
(Figures 3D–3F). Moreover, we assessed ‘‘stabilized’’ microtu-
bules and found a sharp decrease in acetylated tubulin in
Rasip1- or Arhgap29-depleted cells (Figures 3G–3J). This effect
was also surprisingly detectable in vivo in E9.5 Rasip1/ whole
embryo lysates (Figure 3K). Rasip1 and Arhgap29 therefore are
both independently required for cellular structure and contrac-
tility of ECs.
We next examined possible Rasip1 modulation of myosin II.
We reasoned that myosin II activity was likely to be altered
because of four findings: (1) Rasip1 binds both a RhoA-specific
GAP (Arhgap29) and NMHCIIA, which is RhoA-dependent (Fig-
ure 2A); (2) activated RhoA levels were increased in Rasip1/
Arhgap29-depleted cells (Figure 2G); (3) stress fiber assembly
(known to be RhoA dependent) was significantly increased
in Rasip1/Arhgap29-depleted cells (Figures 3D–3F); and (4)
Rasip1/Arhgap29-depleted cells display dramatically decreased
acetylated tubulin (Figures 3G–3J) and NMHCIIA is known to
suppress tubulin acetylation (Even-Ram et al., 2007). We thus530 Developmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Iexamined Rasip1 and Arhgap29 modulation of RhoA-dependant
myosin II via the regulatory molecules Rho-kinase (ROCK) and
the ROCK substrate Myosin Light Chain (MLC) (Matsumura,
2005; Rikitake and Liao, 2005). Phosphorylated MLC (pMLC) is
required for nonmuscle myosin II activity and regulation of the
actomyosin complex.
Indeed, we found significantly increased levels of pMYPT
(T696) (downstream target of ROCK1/2) and pMLC (T18/S19)
in the absence of either Rasip1 or Arhgap29 (Figure 3L and
3M). These data further support the hypothesis that myosin IIA
activity, not localization, depends on Rasip1 and Arhgap29. In
addition, hyperactivation of ROCK/MLC/myosin IIA, and the
manifested cytoskeletal alterations, suggest that an important
function of Rasip1/Arhgap29 is to suppress ROCK, MLC, and
thus, nonmuscle myosin IIA activity via RhoA, during endothelial
morphogenesis.
To confirm whether Rasip1 suppression of RhoA signaling
played a role during EC lumen formation, we knocked down
expression of RhoA in the background of Rasip1 or Arhgap29
loss-of-function. While siRasip1- and siArhgap29-treated cells
were blocked in their ability to form lumens in vitro (as shown
above), this failure was reversed upon coexpression of domi-
nant-negative RhoA (Figure 3N). By contrast, dominant negative
Cdc42 or Rac1 constructs (Bayless and Davis, 2002) had no
effect. These results were further confirmed with co-siRNA treat-
ments to simultaneously knockdown expression of RhoA and
either Rasip1 or Arhgap29 (Figure 3O). Thus, while siRhoA alone
had no effect on in vitro lumen formation, it largely rescued the
absence of either Rasip1 or Arhgap29.
Failure of EC-ECM Adhesion In Vitro in the Absence
of Rasip1 or Arhgap29
As RhoA and NMHCIIA are both known to regulate cell adhesion,
we examined both EC-EC and EC-ECM adhesion in Rasip1/
Arhgap29-depleted cells. Flow cytometry indicated neither
PECAM nor VE-cadherin levels were altered in the absence of
Rasip1 or Arhgap29 (Figures S5A and S5B). In addition, despite
irregular borders, relatively normal levels of the adhesion mole-
cules ZO-1, b-catenin, and PECAM were found at cell-cell inter-
faces of Rasip1- or Arhgap29-depleted cells (Figures S5C–S5K),
suggesting at least grossly that EC-EC adhesion was not
reduced.
By contrast, we found that siRNA-treated ECs exhibited signif-
icantly reduced adhesion to several types of ECM (Figures S6A
and S6B). To assess the molecular machinery that regulates
cell adhesion to ECM, we examined focal adhesions, which are
structures essential for adhesion of cells to matrix during both
embryonic development and blood vessel formation (Bohnsack
and Hirschi, 2003; Goody and Henry, 2010). Focal adhesions
first appear as adhesion complexes (FXs), which mature into
focal adhesions (FAs) and then into fibrillar adhesions (FBs)
(Tomar and Schlaepfer, 2009). An excellent indicator of imma-
ture FX is phosphorylated paxillin (pPaxillin), which is recruited
to nascent FXs, but lost as they mature (Zaidel-Bar et al.,
2007). We found that pPaxillin (Y118)-positive FXs were
expanded in siRasip1- or siArhgap29-depleted cells compared
to control siRNA-treated cells (Figures 4A–4C), especially at
the cell periphery (Figures 4D–4F). In addition, total levels of
pPaxillin (Y118) were significantly increased in the absence ofnc.
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Figure 3. Rasip1 and Arhgap29 Regulate EC Architecture and Tubulogenesis through Rho Family GTPases
(A–F) Immunofluorescent phalloidin staining showing gross cell morphology and stress fibers in siRNA-treated HUVECs.
(G–I) ‘‘Stabilized’’ microtubule shown by acetylated a-tubulin staining in siRNA-treated HUVECs. Insets, high magnification view of microtubules. Nuclei,
DAPI (blue).
(J and K) Acetylated a-tubulin level is downregulated in siRNA treated ECs in vitro (J) and in vivo in E9.5 Rasip1/ embryos (K), n = 2.
(L andM) Western blots showing RhoA and ROCK activity (pMYPT, T696) and phosphorylation of myosin light chain (pMLC, T18/S19) in siRNA-treated HUVECs,
n = 3.
(N) Dominant-negative (DN) RhoA rescues in vitro lumenless phenotype in 3D collagen matrices in siRasip1-/siArhgap29-treated HUVECs.
(O) Loss of Rasip1, which causes a lumenless EC phenotype in 3D collagen matrices, is rescued by siRNA knockdown of RhoA. Error bars represent standard
deviation.
See also Figure S4.
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Rasip1 Directs Vascular TubulogenesisRasip1 or Arhgap29, both in vitro and in vivo (Figure 4G), indi-
cating a likely increase in immature FXs. Of note, it has been
reported that in plated cells, FXs are born at the cell periphery
and mature into FBs at the center of cell (Tomar and Schlaepfer,
2009), suggesting that in the absence of either Rasip1 or
Arhgap29, FX are favored over FAs/FBs and maturation of adhe-
sions is inhibited.
We then assessed mature focal adhesions (FBs), which
contain clustered or ‘‘activated’’ integrins, but lack paxillin
(Morgan et al., 2009). Given the central role of b1 integrin (b1)
in adhesion of ECs to ECM, as well as in blood vessel formation
(Drake et al., 1992; Zovein et al., 2010), we examined activated
b1 using an ‘‘activated’’ state-specific antibody, 9EG7 (Bazzoni
et al., 1995). In the absence of either Rasip1 or Arhgap29, acti-Devevated b1 integrin levels were reduced 70% and 80%, respec-
tively (Figure 4H, black columns). To reveal total cell-surface
b1 integrin levels, we artificially activated b1 using manganese
(Lenter et al., 1993) and found these unchanged (Figure 4H,white
columns). These results suggest that Rasip1 is required for acti-
vation, rather than levels, of b1 integrin.
We further examined the reduction of activated b1 integrin in
Rasip1/Arhgap29-depleted ECs using immunofluorescent stain-
ing with 9EG7. Control HUVECs displayed FBs as linear tracts of
clustered b1 integrin in the central region of the cell (Figure 4I). By
contrast, siRasip1- or siArhgap29-treated cells lacked all FB
organization into tracts, showing only reduced and punctate b1
foci (Figure 4J and 4K). This effect was similarly observed in
another EC line, MS1 (Figures S6C–S6E). Thus, activated b1lopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 531
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Figure 4. Rasip1 and Arhgap29 Are Required for Maturation of Endothelial-ECM Adhesion
(A–F) Immature focal adhesions shown by phosphorylated Paxillin (Y118) staining in siRNA-treated HUVECs.
(G) Phosphorylated Paxillin (Y118) is upregulated in siRNA treated ECs in vitro and in vivo in Rasip1/ embryos, n = 2.
(H) Flow cytometry showing decrease in activated b1 integrin (9EG7) in the absence of Rasip1 or Arhgap29. MnCl2 (5 mM) treatment reveals total surface levels of
integrins are unchanged.
(I–K) Mature fibrillar adhesions shown by activated b1 integrin (9EG7) expression in siRNA-treated HUVECs. Insets, highmagnification view of 9EG7+ FBs. Nuclei,
DAPI (blue). Error bars represent standard deviation.
See also Figures S5 and S6.
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Rasip1 Directs Vascular Tubulogenesislevels and distribution were severely affected in the absence of
Rasip1 or Arhgap29, although total b1 remained unchanged
(including in vivo, Figures S6F and S6G). Given that failure to
disassemble FX is known to block FB formation and b1 activation
(Zaidel-Bar et al., 2007), our data suggested that the lack of FB
tracts observed in siRNA-treated cells was likely because of
a failure of FX disassembly.
To test whether integrin activation specifically required RhoA
and/or nonmuscle myosin IIA suppression, we attempted to
rescue integrin activation with either blebbistatin (nonmuscle
myosin II inhibitor) (Straight et al., 2003) or Y-27632 (ROCK inhib-
itor) (Rikitake and Liao, 2005). While both drugs partially rescued
b1 integrin activation, neither did so well, implicating possible
integrin redundancy and a requirement for additional signaling
pathways (Figure S6H).
We therefore asked whether other integrins, such as b3, might
also depend on Rasip1. We examined avb3 in siRNA-treated
cells by flow cytometry using the antibody LM609 (Byron et al.,
2009). A significant decrease in b3 in untreated (Figure S6I, black
columns) versus manganese-treated cultures (Figure S6I, white
columns) suggested that activated b3 depended on Rasip1/
Arhgap29 activity. We thus examined activated avb3 integrin
using an activated state-specific antibody, WOW-1 (Kiosses
et al., 2001) and observed a modest but measurable decrease
in levels in siRNA-treated cells (data not shown). Similarly, bleb-
bistatin and Y-27632 treatment showed a trend toward rescue,
although it was not statistically significant (Figure S6J). These532 Developmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Idata suggest that Rasip1 and Arhgap29 work together to regu-
late EC adhesion to the surrounding ECM, likely via b1 and
possibly other integrins, and in the absence of either molecule
the dynamic maturation of adhesion contacts is compromised,
reducing EC-ECM adhesion.
Rasip1 Is Required for Proper In Vivo Endothelial-ECM
Adhesion
To validate our in vitro findings that Rasip1 regulates EC adhe-
sion, we examined the interface between adjacent embryonic
ECs (EC-EC), as well as between ECs and surrounding ECM
(EC-ECM), in Rasip1+/ and Rasip1/ embryos. Given that tight
junctions (TJs) and adherens junctions (AJs) components play
critical roles in epithelial lumen formation (Lampugnani et al.,
2010), we first examined in vivo EC-EC junctions. While clau-
din-5 and ZO-1 (TJs) highlighted narrow peripheral junctions
between wild-type aortal ECs at E8.5 (Figures 5A, 5A0, 5C, and
5C0), TJs were found in clusters at the center of Rasip1/ cords
(Figures 5B, 5B0, 5D and 5D0). Similarly, VE-cadherin (AJs) was
normally only at peripheral junctions (Figures 5E and 5E0);
however, it was ectopically distributed in Rasip1/ cords
(Figures 5F and 5F0). E8.5 mutant aortic ECs also remained
distinctly cuboidal, similar to b1-depleted ECs (Zovein et al.,
2010) (Figures 5C–5F0 and data not shown).
We found the opposite situation when we examined adhesion
of ECs to the surrounding matrix. Aortic cords normally undergo
tubulogenesis in immediate contact with both collagen IV andnc.
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Figure 5. Rasip1–/– Angioblasts Remain Cuboidal and Fail to Adhere to Surrounding ECM
(A–N) Confocal immunofluorescencemicroscopy of 3–6 somiteRasip1+/ (A, C, E, G, I, K, andM) andRasip1/ (B, D, F, H, J, L, and N) dorsal aortae (Flk1-EGFP,
A, B, G, H, I, J, K, M, and N) in transverse sections: (A and B) claudin-5, (C and D) ZO-1 and laminin, (E and F) VE-cadherin and collagen IV, and (G and H) fibro-
nectin. Nuclei, DAPI (blue). (O) Average dorsal aortae diameter at 6–8 somite stage, n = 30. Arrows, EC-EC junctions in Rasip1+/ embryos; arrowheads,
mislocalized EC-EC junctions. Scale bars, 25 mm. Error bars represent standard deviation.
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Rasip1 Directs Vascular Tubulogenesisfibronectin (FN), which are secreted by the surrounding trunk
mesenchyme, as well as laminin secreted by the underlying
endoderm. While Rasip1/ aortic ECs remained tightly associ-
ated with the endoderm, mutant ECs lost adherence to the
surrounding mesoderm (Figures 5D, 5F, 5H, 5L, and 5N). This
selective failure of EC-ECM adhesion was observed at all stages
after 3S during vasculogenesis. At 3S, bothwild-type andmutant
cord ECs were in contact with mesenchymal cells in a nearly
identical manner (Figures 5I and 5J). However, between 4S to
6S, an intervening space progressively expanded (Figures
5K–5N). Indeed, while ECs remained in tight contact with the
endoderm, a highly reproducible and growing cavity appearedDevebetween the mesenchyme and the Rasip1/ aortic cord ECs.
Because of the failure of the aortae to acquire patency, the dia-
meter of these cords was reduced compared to wild-type, with
most of them under 5 mm (Figure 5O). Together, these data
suggest the interesting possibility that the overlying mesen-
chyme provides structural support, via integrins, to the expand-
ing aortic endothelial tubes.
Rasip1 Is Required for Establishment of Endothelial
Apicobasal Polarity
Because junctional proteins were mislocalized along the apical/
luminal surface of Rasip1/ ECs and becauseGTPase activity islopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 533
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Figure 6. Rasip1–/– Angioblasts Display Defective Cell Polarity and Fail to Localize Junctional Proteins to Cord Periphery
(A– L) Confocal immunofluorescence microscopy of Rasip1+/ (A, C, G, I, and K) and Rasip1/ (B, D, H, J, and L) aortic ECs in transverse sections: podocalyxin
(green), ZO-1 (red), and Par3 (G-L, red). Nuclei, DAPI (blue). (E and F) Rasip1 null aortic cord angioblasts display mislocalized EC-EC TJs. TEM images of trans-
verse sections ofRasip1+/ (E) andRasip1/ (F) littermates at 4-somite stage. (E and F) Black arrows, tight junctions; white arrows, slits/isolated lumens between
ECs. (A00, D00, and J) Arrows, ectopic basal TJs; arrowheads, ectopic apical TJs; dotted line, basal endoderm surface. Scale bars, 5 mm (A–J), 20 mm (K and L).
See also Figure S7.
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Rasip1 Directs Vascular Tubulogenesisknown to control cell polarity (Etienne-Manneville and Hall,
2002), we asked whether EC apicobasal polarity depended on
Rasip1. We first examined expression of recently described
endothelial apical molecules, shown to drive vascular lumen
formation (Strilic et al., 2009). We found that both CD34 and
F-actin localized normally in Rasip1/ aortic ECs (Figures
S7A–S7D). In addition, both moesin and podocalyxin (PODXL)
displayed normal localization, being primarily expressed along
EC surfaces facing the cord center (apical) in both wild-type
and Rasip1/ vessels (Figures S7E–S7L).
The presence of TJs in the center of Rasip1/ cords,
however, suggested EC polarity defects. We examined initiation
of lumen formation in wild-type cords and found early clearance
of TJs (ZO-1) at the cord center, at 2S (Figures 6A–6A00). Thus,
ECs rapidly refine their apicobasal character during lumen
formation, with junctional ZO-1 segregating from apical PODXL.
In contrast, Rasip1/ cords displayed a distinct failure to clear
the apical membrane of TJs as lumen formation initiated (Figures
6B–6B00). This ectopic localization of ZO-1 persisted in mutant
cords in older embryos (Figures S7M–S7N00). Aberrant apical
localization of the normally junctional ZO-1 molecules was
particularly striking upon costaining with the apical marker
PODXL. In wild-type ECs, the two quickly segregated during
lumen formation, with ZO-1 at the cord periphery and PODXL
along internal surfaces (Figures 6C–6C00). However, in Rasip1/
ECs, the two exhibited significant sustained overlap (Fig-
ure 6D–6D00). ZO-1 was not only ectopically located on apical,
but also basal, EC surfaces. Transmission electron microscopy
(TEM) studies also revealed failure of the cord-to-tube transition
at early stages of morphogenesis (4S stage), revealing slit-like
lumenal spaces and mislocalized cell-cell junctions (Figures 6E534 Developmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Iand 6F) and confirming that ectopic localization of ZO-1 repre-
sents ectopic junctions.
We examined cell polarity in Rasip1/ ECs by assessing the
polarity determinant Par3. As EC polarity was recently shown
to be disrupted (and Par3 expression reduced) in b1 integrin
null ECs (Zovein et al., 2010), we asked whether Par3 expression
or localization depends on Rasip1. In wild-type aortic ECs, like
ZO-1, Par3 was expressed along the entire apical membrane
prior to lumen formation, but redistributed junctionally (apicolat-
erally) as vascular lumens formed (Figures 6G, 6I, and 6K). These
results were consistent with reports that Par3 localizes to TJs in
polarized epithelial cells (Jaffe et al., 2008). In Rasip1/ ECs, by
contrast, Par3 initially localized normally to the apical, prelumen
EC surface, but it subsequently failed to be cleared during lumen
formation (Figures 6H, 6J, and 6L). Par3 could be observed, like
ZO-1, in clusters between apposed ECs along the apical
membrane. Interestingly, occasionally we observed proper TJ
localization in Rasip1 null ECs, and in these rare instances,
lumens formed normally (Figure S7O). However, these isolated
lumens were small and formed isolated pockets but did not
connect into functional tubes.
DISCUSSION
Here, we identify a critical requirement for Rasip1 during normal
blood vessel tubulogenesis. We show that Rasip1 together with
Arhgap29, a RhoA-specific GAP, suppresses RhoA signaling
anddampensROCKandnonmusclemyosin IIA activities in endo-
thelial cells (Figure 7A). When Rasip1 or Arhgap29 are absent,
RhoA activation is elevated, resulting in excessive actomyosin
contractility, disruption of cell polarity, and consequent failure ofnc.
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Figure 7. Models of Rasip1 Regulation of Embryonic Vascular Tubulogenesis
(A) Rasip1 regulates EC contractility and adhesion by modulating Rho family small GTPases.
(B and C) The balance between EC-EC and EC-ECM adhesion is critical to vascular cord to tube transition. (B) Loss of integrin adhesion at the basal cell surface
and (C) failure of junctional protein redistribution from the apical cell surface to the cord periphery result in failed vascular tubulogenesis.
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Rasip1 Directs Vascular Tubulogenesislumen morphogenesis. Basal adhesion contacts, between ECs
andsurroundingECM, fail tomature (asassessedby lack of integ-
rin activation), resulting in disassociation of endothelium from
surrounding mesenchyme. Apical adhesion is also disrupted, as
junctional contacts are mislocalized within the central portion
of cords, blocking the ability of ECs to open coherent lumens
(Figure 7B). Inappropriate segregation of apicobasal character
is evidenced by sustained overlap of apical and junctional
(lateral)markers inRasip1/ECs. Additionally, Rasip1/Arhgap29
suppressionofRhoApromotesCdc42andRac1activation,which
in turn activates downstreamkinases, including Pak4, Src, B-Raf,
C-Raf, andErk, required for in vitroEC lumen formation (Kohet al.,
2008, 2009). Rasip1 thus represents a unique molecular bottle-
neck, as it integrates Rho family GTPase signaling to control cell
polarity and adhesion, thereby coordinating endothelial morpho-
genesis and blood vessel tubulogenesis.
Rasip Is Required for Endothelial Cell Polarity
Two key points led us to expect defective cell polarity in Rasip1
null angioblasts. First, Rasip1 regulates endothelial GTPase
activity and decades of classical work have demonstrated regu-
lation of cell polarity by Rho GTPases, such as Cdc42 (Etienne-
Manneville and Hall, 2002). Second, recent findings point to the
importance of proper cell polarity during vascular lumen forma-
tion, both in early embryonic vessels, as well as those formed
later during embryogenesis (Strilic et al., 2009; Zovein et al.,
2010).
It was, therefore, surprising to observe no changes in subcel-
lular localization or levels of CD34, F-actin, moesin, or podoca-
lyxin in Rasip1 null cord ECs, as these molecules are localized
to the apical EC surface and are required for lumen formation.
However, disruption of cell polarity in Rasip1 null cord ECs was
indeed revealed by junctional protein mislocalization. Significant
overlap of apical podocalyxin with ZO-1 in Rasip1 null ECs, and
ectopic VE-cadherin, at multiple points along the apical surfaceDeveand at all stages examined (both early and late), showed that the
apical membrane did not properly segregate from the lateral/
junctional membrane. Moreover, basal EC character was also
compromised, as ectopic ZO-1 and VE-cadherin were found
along basal membranes and functional integrin adhesion to the
surrounding matrix was severely reduced.
Cell polarity defects in Rasip1 null cord ECs were further
revealed by mislocalization of the polarity determinant Par3.
Indeed, in the absence of Rasip1, we found a clear failure of
Par3 to segregate normally to cell-cell junctions, away from the
apical membrane. Par3 is known to associate with the aPKC
polarity complex in epithelial cells (Suzuki and Ohno, 2006) and
to be important in establishment of arterial cell polarity (Zovein
et al., 2010). We note that while Par3 was previously found to
be localized basally in older arterial vessels and reduced in the
absence of b1 integrin (Zovein et al., 2010), localization of Par3
in early angioblasts of the dorsal aortae was clearly junctional,
and levels appeared unchanged in Rasip1 null ECs. It is conceiv-
able that vasculogenic vessels form differently than later angio-
genic vessels but that key signaling molecules are nonetheless
conserved.
We note that between clusters of junctional molecules (ZO-1/
Par3/VE-cadherin), we observed slit-like openings in which
apical molecules like podocalyxin/moesin were expressed
normally. We speculate that much of the lumen formationmolec-
ular pathway actually occurs ‘‘normally’’ in the absence of
Rasip1, albeit discontinuously. In Rasip1 null ECs, TJ/AJ locali-
zation likely occurs stochastically, such that the morphogenetic
process is short-circuited, blocking functional lumen formation
and tubulogenesis.
RasipRegulation of Cell Adhesion to ECMviaMaturation
of Adhesion Contacts
The primary defect observed in ECs in the absence of Rasip1
function is failure of proper EC adhesion regulation, bothlopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 535
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Rasip1 Directs Vascular Tubulogenesisbetween cells andwith surroundingmatrix. Failure of adhesion to
matrix was evident both in live cell imaging of in vitro EC lumen
formation in siRasip1-treated cells, as well as in sections of
Rasip1/ lumenless aortic cords. This EC-ECM failure was
particularly striking in collagen 3D cultures, as ECs extended
processes that transiently adhered to the surrounding matrix
as they initiated lumen formation but snapped back and
collapsed repeatedly as they lost traction. These behavioral
effects can be explained by impaired focal adhesion maturation
in Rasip1-depleted cells. Whether resulting immature focal
adhesions are merely weaker, or whether outside-in or inside-
out signaling via focal adhesion components is compromised,
cannot be distinguishable from these studies. It will be inter-
esting to identify additional Rasip1-binding partners, as it can
complex with a number of Rho and Ras family GTPases (Mitin
et al., 2004), and further dissect signaling pathways and their
effects on cell adhesion and architecture.
An interesting point regarding maturation of endothelial adhe-
sion contacts is that Rasip1 appears to promote engagement
of multiple integrins. Specifically, decrease of both b1 and
avb3 in siRasip1-depleted cells suggests other integrins are
likely similarly regulated. Lumen dependence on multiple integ-
rins is supported by antibody-based knockdowns targeting b1
(Drake et al., 1992) or avb3 (Drake et al., 1995), which blocked
lumen formation in chick aortae. Redundancy of integrin depen-
dence on Rasip1 during lumen formation likely explains the
more profoundly compromised vascular phenotype observed
in Rasip1/ mice versus EC-specific deletions of single integ-
rins, which have not shown global lumen failure (Carlson et al.,
2008; Tanjore et al., 2008). In Rasip1/ aortae, we suggest all
required integrins have been blocked, as Rasip1 controls their
activation. One relevant study bypassed the issue of integrin
redundancy by examining fibronectin (FN) null embryos, as FN
is a common ligand for a number of integrins, including b1 and
avb3 (George et al., 1997). Interestingly, the endocardial lumen
was absent in FN/ embryos, and aortic ECs partially detached
from surrounding mesenchyme, similar to Rasip1 null embryos.
However, Rasip1/ do not phenocopy FN/ embryos, likely
because other matrix components are also required. Together,
these data suggest that Rasip1 is critical to integrin function
in ECs.
Diverse Cellular Mechanisms Drive Vascular Lumen
Formation?
An unexpected finding in our studies involved the growing gap
between the trunk mesenchyme and the lumenless Rasip1/
aortic cords. Our data suggest that Rasip1-deficient aortic ECs
are unable to maintain proper integrin-mediated adhesion to
the surrounding mesenchymal ECM and imply that the mesen-
chyme actively provides support during lumen expansion. We
note that while this gap is pronounced surrounding the mutant
aortic cords, similar gaps around other vessels are variable or
absent, such as those in the yolk sac. It is therefore possible
that different blood vessels create lumens by different cellular
mechanisms but common molecular mechanisms.
Indeed, other biological ‘‘tubes’’ often depend on multiple
spatially and/or temporally specific mechanisms for lumen
formation. The Drosophila trachea, for instance, ranges from
intracellular vacuole-based lumen generation in fine terminal536 Developmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Icells to multicellular budding and lumen expansion in primary
tracheal branches (Lubarsky and Krasnow, 2003). Therefore,
although we present here a mechanism for lumen formation
based on angioblast adhesion regulation, we predict that the
highly complex and heterogeneous developing vascular system
(Aird, 2007) will exhibit regional differences with respect to the
cellular mechanisms employed to generate lumens.
Indeed, controversy has emerged in the field of vascular
biology regarding how vascular lumens form. Some observa-
tions, both in vitro and in vivo, have suggested that lumen forma-
tion occurs via intracellular vacuoles, which emerge and fuse
(Davis and Bayless, 2003; Kamei et al., 2006). Other observa-
tions have favored a mechanism based on angioblast cords
rearranging their junctions to the periphery and opening up
a central lumen based on active cytoskeletal forces (Jin et al.,
2005; Strilic et al., 2009). Our in vivo observations of murine
aortic ECs reveal no evidence for vacuole fusion, similar to (Strilic
et al., 2009). However, cultured ECs in 3Dmatrices clearly exhibit
vacuole fusion (seen in Movies S1–S6). Of great interest then is
that failure of lumen formation in both systems occurs in the
absence of Rasip1. This places Rasip1 in a critical regulatory
position over the molecular machinery that controls cellular
processes, such as the cell polarity, cytoskeleton (i.e., cell
shape), and localization or robustness of cell junctions and adhe-
sion contacts. Future studies will be aimed at identifying
commonalities and differences in different EC types.
Rasip1 Regulation of GTPase Signaling
Our data suggest that Rasip1 suppresses RhoA (known to inhibit
lumen formation) and promotes activation of Cdc42 and Rac1
(both known positively mediate lumen formation). Rescue exper-
iments demonstrate that failure of tubulogenesis in the absence
of either Rasip1, or its effector Arhgap29, can be fully restored by
dominant-negative RhoA or siRhoA treatment.
As a consequence, we have focused on Rasip1 regulation of
RhoA signaling. However, the sharp decrease in Cdc42 and
Rac1 activity in the absence of Rasip1 is of particular interest,
as these GTPases play direct roles in assembly and disassembly
of junctional components, as well as cytoarchitecture such as
filopodia formation (Popoff and Geny, 2009). Indeed, we see
decreased filopodia in the absence of Rasip1 function (data
not shown). In addition, Cdc42 has been directly linked to main-
tenance of EC-EC junctions via VE-cadherin (Broman et al.,
2006), as well as vacuole-based lumen formation (Bayless and
Davis, 2002). However, we identified no relevant effectors for
Cdc42 or Rac1 as binding partners in our mass spectrometry
screen; therefore, it is possible that their regulation by Rasip1
is indirect and occurs via the RhoA pathway.
Critical Role of Actomyosin Contractility for Vascular
Tubulogenesis
One likely critical effector of vascular tubulogenesis is the RhoA-
specific GAP and Rasip1 binding partner Arhgap29, which
suppresses RhoA signaling specifically in developing blood
vessels. Finding that Rasip1 also bound NMHCIIA, which is
regulated by RhoA, raises the distinct possibility that a key role
of Rasip1 is to suppress actomyosin contractility via suppres-
sion of RhoA. This is an appealing model, as angioblasts
must dramatically change their shape during lumen formation,nc.
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Rasip1 Directs Vascular Tubulogenesistransforming from an initially rounded cuboidal morphology to an
exceedingly flattened one. Increased intracellular contractility
would inhibit such a shape change. The recent report that
NMHCIIA recruitment to the luminal surface of ECswas defective
in the lumenless cords of VEGF heterozygotes (Strilic et al., 2009)
adds another interesting dimension to the role of contractility
during lumen formation. In this case, lack of contractility fails to
‘‘bend’’ the luminal membrane and ‘‘open up’’ the central lumen.
Together, the data suggests that precisely controlled levels of
myosin II activity, and contractility, are required for vascular
lumens: too much contractility (as in Rasip1/ ECs) or too little
contractility (as in VEGF+/ ECs) both lead to lumen failure.
Conclusions
Rasip1 therefore actsasaunique, endothelial-specific, integration
node for Rho GTPase signaling, controlling EC morphogenesis
from cord-to-patent blood vessel via cell polarity and adhesion
regulation. Given that most approaches to antiangiogenic thera-
pies have focused on targeting extrinsic growth factors, such as
VEGF, rather than cell-intrinsic effects, future studies of Rasip1
and the molecular circuitry under its control, hold great promise
to provide tools and models for furthering clinical therapies.
EXPERIMENTAL PROCEDURES
Generation of Rasip1 Null Allele
The mouse 129sv genomic DNAs (provided by UTSW transgenic core) were
used as template for the generation of a conditionally null allele by amplifying
a region of DNA flanking exon 3 and two additional homologous arms 50 and 30
using Takara’s LA Taq polymerase. The three subclones were cloned into
a neomycin/thymidine kinase double selection vector pGKneo-TK2-Floxed-
Flip (kindly provided by T. Carroll). The exon 3 containing subclone was
inserted into a multiple cloning site flanked by loxP sites. Neomycin resistance
cassette was designed being flanked by Flp recombinase target (FRT) sites for
removing if necessary. This targeting vector was electroporated into mouse
embryonic stem cells by UTSW transgenic core. 50 and 30 external probes
for Southern blot screening were PCR-amplified and subcloned into pGEM-
T-Easy vector (Invitrogen). SphI-digested purified genomic DNA from each
clones was screened by Southern blot using both probes for homologous
recombination. The correct clone was injected into C57BL6/J blastocysts for
generating Rasip1 targeted mouse line. After germ line transmission confirma-
tion, the animals were bred with Sox2-Cre mice (kindly provided by T. Carroll)
to generate a Rasip1 null allele. Litters were genotyped by PCR using primers
listed in the Supplemental Experimental Procedures. The wild-type, floxed,
and null alleles give bands of 165 base pairs, 247 base pairs, and 331 base
pairs, respectively.
Embryo Histology and In Situ Hybridization
Mouse, frog, and zebrafish in situs and mouse beta-galactosidase staining
were performed as previously described (Neumann et al., 2009; Xu et al.,
2009a). All cloning primers are listed in the Supplemental Experimental Proce-
dures. Connexin40 (Gja5) clone was obtained from Open Biosystems
(MMM1013-9202306).
Cell Culture
Human umbilical vein ECs (HUVEC, PCS100-010) and mouse pancreatic islet
EC line MILE SVEN 1 (MS1, CRL-2279) were obtained from ATCC (or Lonza)
and cultured per ATCC’s standard protocols. 293AD cells (kindly provided
by E. Olson) were grown in Dulbecco’s modified Eagle medium (DMEM,
GIBCO) with 10% Fetal Bovine Serum (FBS).
Establishment of MS1Rasip1-FLAG Cell Line
C-terminal FLAG-taggedRasip1 cassette was inserted into pEN_TTmiRc2 and
then subcloned into pSLIK-Neo (kindly provided by Z. Chen) by gatewayDevecloning. Ten micrograms of Rasip1-FLAG expressing pSLIK vector was trans-
fected into 293AD cells together with 7.5 mg of each of the two packaging
plasmids pLp1 and pLp2, and 5 mg of the vesicular stomatitis virus (VSV)
G envelope plasmid pLp-VSVG was diluted in Opti-MEM (Invitrogen). The
medium was changed 12 hr posttransfection, and the viral particles were
harvested and filtered through 45 micron microfilters upon applying to
MS1 ECs for infection. The infected MS1 cells were selected with 4 mg/ml
G418 (Sigma), and the expression of Rasip1-FLAG were analyzed by western
blot and immunofluorescent staining using a monoclonal anti-M2 antibody
(Sigma).
Tandem Affinity Purification of Rasip1 Complex
MS1Rasip1-FLAG cells were cultured with the presence of 1mg/ml doxycyclin for
3 days to induce the expression of exogenous Rasip1-FLAG fusion protein.
The cell lysate from ten 10 cm dishes were incubated with 50 ml Anti-FLAG
M2 Affinity Gel (Sigma A2220) as per Sigma’s standard protocol. The bound
proteins were eluted with 200 ml 0.2 mg/ml FLAG peptide (Sigma F3290).
The elutes were then incubated with 5 mg Rasip1 antibody (Abcam ab21018)
or IgG agarose (Sigma A0919, for control) at 4C for 1 hr. The Rasip1 antibody
bound protein complex were then incubated with 50 ml rec-Protein G Sephar-
ose 4B (Zymed 10-1241) at 4C for 1 hr, followed by elution with 40 ml 0.1mg/ml
human RASIP1 immunizing peptide (aa951-962, UTSW Peptide Synthesis
Core Facility). The final elutes were resolved by SDS-PAGE and processed
by silver staining using Invitrogen’s SilverQuest kit (LC6070). Specific bands
were cut off and subjected to Mass Spectrometry as previously published
(Xu et al., 2009b).
siRNA Transfection
siRNAs obtained from IdtDNA, Invitrogen, and Dharmacon were transfected
into cultured endothelial cells using standard protocol as previously described
(Koh et al., 2008). Sequences of siRNAs are listed in Supplemental Experi-
mental Procedures.
Immunofluorescent Staining
Immunufluorescent staining in tissueswas performed as per standard protocol
previously published (Villasenor et al., 2008). Antibodies used in this study can
be found in Supplemental Experimental Procedures.
In Vitro Lumen Formation and Pull-Down Assays
HUVEC (human umbilical vein endothelial cell) lumen and tube formation in 3D
collagen matrices were performed as previously described (Koh et al., 2009).
TEM
TEM was carried out by UTSW Electron Microscopy Core Facility as per their
standard protocols.
Flow Cytometry
HUVECs detached from the dish by 50 mM EDTA (pH 8.0) treatment were
washed with and resuspended as 107/ml in labeling buffer (Ca2+ free PBS con-
taining 0.5% BSA). After incubation at 37C for 15 min with or without 5 mM
MnCl2, the cells were labeled with primary antibodies at 1:50 for 30 min on
ice. Cells were then washed twice and labeled with fluorophore-conjugated
secondary antibody in labeling buffer at 4C for 30 min. After final wash (twice
in chilled PBS), cells were resuspended in 500 ml 1% PFA and subjected to
FACS analysis (UTSW Flow Cytometry Facility). Blebbistatin and Y-27632
were kindly provided by H. Yin.
Microscopy, Imaging, and Statistical Analysis for In Vitro Lumen
Formation
Visualization and image acquisition of EC lumen formation was performed
using an inverted microscope (CKX41: Olympus), and real time-lapse imaging
of ECs undergoing lumen and tube formation was done using a Nikon
TE2000-E system with a temperature-controlled chamber. Image analysis
was performed using MetaMorph software. Statistical analysis of EC vasculo-
genesis was performed using SPSS 11.0 software. Statistical significances
were assessed by a paired-samples t test.lopmental Cell 20, 526–539, April 19, 2011 ª2011 Elsevier Inc. 537
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